Stock Track | Moderna Soars 5.33% Intraday on Science Day Catalysts and Flu Vaccine Approval Expectations

Stock Track07-01 22:47

Moderna, Inc. (MRNA) saw its stock price soar 5.33% during intraday trading on Wednesday, marking a significant upward movement for the biopharmaceutical company.

The rally is attributed to continued positive momentum from several recent developments. The company's Science Day event, held on June 25, served as a key catalyst, where Moderna disclosed its in-vivo CAR-T project mRNA-6007 for the first time. This project targets B-cell mediated autoimmune diseases and is planned to enter clinical trials next year. The event also showcased an extensive pipeline including tumor vaccines, cancer prevention vaccines, and an AI-powered R&D platform, reinforcing the market's view of Moderna's transition into a platform biopharmaceutical enterprise. Following the event, analysts at Piper Sandler and Jefferies raised their price targets on the stock.

Further supporting the positive sentiment is the recent unanimous recommendation (9-0) by an FDA advisory committee for the approval of Moderna's seasonal influenza vaccine, mRNA-1010, for adults aged 50 and older. A final FDA decision is expected by early August. In preparation for potential new product launches, the company has also appointed a new Chief Commercial Officer and reorganized its operational structure.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1116604157?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-01 22:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116604157","market":"nz","top_or_hot":-1,"title":"Stock Track | Moderna Soars 5.33% Intraday on Science Day Catalysts and Flu Vaccine Approval Expectations","media":"Stock Track","content":"<p>Moderna, Inc. (MRNA) saw its stock price soar 5.33% during intraday trading on Wednesday, marking a significant upward movement for the biopharmaceutical company.</p><p>The rally is attributed to continued positive momentum from several recent developments. The company's Science Day event, held on June 25, served as a key catalyst, where Moderna disclosed its in-vivo CAR-T project mRNA-6007 for the first time. This project targets B-cell mediated autoimmune diseases and is planned to enter clinical trials next year. The event also showcased an extensive pipeline including tumor vaccines, cancer prevention vaccines, and an AI-powered R&D platform, reinforcing the market's view of Moderna's transition into a platform biopharmaceutical enterprise. Following the event, analysts at Piper Sandler and Jefferies raised their price targets on the stock.</p><p>Further supporting the positive sentiment is the recent unanimous recommendation (9-0) by an FDA advisory committee for the approval of Moderna's seasonal influenza vaccine, mRNA-1010, for adults aged 50 and older. A final FDA decision is expected by early August. In preparation for potential new product launches, the company has also appointed a new Chief Commercial Officer and reorganized its operational structure.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Moderna Soars 5.33% Intraday on Science Day Catalysts and Flu Vaccine Approval Expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Moderna Soars 5.33% Intraday on Science Day Catalysts and Flu Vaccine Approval Expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-07-01 22:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna, Inc. (MRNA) saw its stock price soar 5.33% during intraday trading on Wednesday, marking a significant upward movement for the biopharmaceutical company.</p><p>The rally is attributed to continued positive momentum from several recent developments. The company's Science Day event, held on June 25, served as a key catalyst, where Moderna disclosed its in-vivo CAR-T project mRNA-6007 for the first time. This project targets B-cell mediated autoimmune diseases and is planned to enter clinical trials next year. The event also showcased an extensive pipeline including tumor vaccines, cancer prevention vaccines, and an AI-powered R&D platform, reinforcing the market's view of Moderna's transition into a platform biopharmaceutical enterprise. Following the event, analysts at Piper Sandler and Jefferies raised their price targets on the stock.</p><p>Further supporting the positive sentiment is the recent unanimous recommendation (9-0) by an FDA advisory committee for the approval of Moderna's seasonal influenza vaccine, mRNA-1010, for adults aged 50 and older. A final FDA decision is expected by early August. In preparation for potential new product launches, the company has also appointed a new Chief Commercial Officer and reorganized its operational structure.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"","article_id":"1116604157","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116604157","pubTimestamp":1782917242,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Moderna, Inc. (MRNA) saw its stock price soar 5.33% during intraday trading on Wednesday, marking a significant upward movement for the biopharmaceutical company.The rally is attributed to continued...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"个股追踪|Moderna盘中大涨5.33%受科学日催化剂及流感疫苗获批预期影响","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1},"content_text":"Moderna, Inc. (MRNA) saw its stock price soar 5.33% during intraday trading on Wednesday, marking a significant upward movement for the biopharmaceutical company.The rally is attributed to continued positive momentum from several recent developments. The company's Science Day event, held on June 25, served as a key catalyst, where Moderna disclosed its in-vivo CAR-T project mRNA-6007 for the first time. This project targets B-cell mediated autoimmune diseases and is planned to enter clinical trials next year. The event also showcased an extensive pipeline including tumor vaccines, cancer prevention vaccines, and an AI-powered R&D platform, reinforcing the market's view of Moderna's transition into a platform biopharmaceutical enterprise. Following the event, analysts at Piper Sandler and Jefferies raised their price targets on the stock.Further supporting the positive sentiment is the recent unanimous recommendation (9-0) by an FDA advisory committee for the approval of Moderna's seasonal influenza vaccine, mRNA-1010, for adults aged 50 and older. A final FDA decision is expected by early August. In preparation for potential new product launches, the company has also appointed a new Chief Commercial Officer and reorganized its operational structure.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1116604157","isCrawlerRequest":true}